...
首页> 外文期刊>Drug discovery today. Disease models >Human ESC/iPSC-based 'omics' and bioinformatics for translational research
【24h】

Human ESC/iPSC-based 'omics' and bioinformatics for translational research

机译:基于人的ESC / IPSC的“OMIC”和转化研究的生物信息学

获取原文
获取原文并翻译 | 示例
           

摘要

The establishment of human embryonic stem cell lines (hESCs) created the basis for new approaches in regenerative medicine and drug discovery. Despite the potential of hESCs for cell-based therapies, ethical controversies limit their use. These obstacles could be overcome by induced pluripotent stem cells (iPSCs) that are generated by reprogramming somatic cells. Before iPSCs can be used for clinical applications, however, they must be thoroughly analyzed for aberrations in the genome, epigenome, transcriptome and proteome. Here, we review how 'omics' technologies can be employed for a quantitative and definitive assessment of these cells.
机译:建立人胚胎干细胞系(HESC)为再生医学和药物发现的新方法创造了基础。 尽管具有基于细胞的疗法的HESC,但伦理争议限制了它们的使用。 通过重编程制造细胞产生的诱导多能干细胞(IPSC)可以克服这些障碍。 然而,在IPSC可用于临床应用之前,必须在基因组,表观蛋白酶,转录组和蛋白质组中彻底分析它们的畸变。 在这里,我们回顾如何使用“OMICS”的技术如何用于这些细胞的定量和明确评估。

著录项

  • 来源
  • 作者单位

    Molecular Oncology Medical School University of Leipzig Leipzig Germany;

    Molecular Cardiology and Stem Cell Unit National Institute on Aging National Institutes of Health;

    Department of Biochemistry Biotechnology and Bioengineering Center Medical College of Wisconsin;

    Molecular Cardiology and Stem Cell Unit National Institute on Aging National Institutes of Health;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号